“…Among six drugs (rivastigmine, galantamine, memantine, donepezil, memantine combined with donepezil, and aducanumab) approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD to date, only aducanumab potentially slows the progression of AD [1]. Many risk factors have been identified contributing to the onset and development of cognitive impairment and dementia, including age, genetics, cardiovascular and cerebral vascular diseases, traumatic brain injury, spinal cord injury, inadequate physical activity or sleep, excessive alcohol use, smoking, depression, and many more [2,3]. In the United States, eleven percent of people age 65 and older have dementia, and an estimated 6.2 million have AD as of 2021.…”